Comparative Pharmacology
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus RECORLEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIOTHYRONINE SODIUM versus RECORLEV.
LIOTHYRONINE SODIUM vs RECORLEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liothyronine is a synthetic form of triiodothyronine (T3), the active thyroid hormone. It binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing basal metabolic rate, oxygen consumption, and thermogenesis. It enhances carbohydrate and lipid metabolism, and promotes normal growth and development.
RECORLEV (levoketoconazole) is an orally administered corticosteroid biosynthesis inhibitor that suppresses cortisol production by inhibiting adrenal and gonadal steroidogenic enzymes, particularly CYP17A1 (17α-hydroxylase and 17,20-lyase) and CYP11B1 (11β-hydroxylase). It also weakly inhibits CYP3A4 and other CYP enzymes.
25-75 mcg orally once daily; initial dose 25 mcg daily, titrate by 12.5-25 mcg increments every 1-2 weeks based on response.
150 mg orally twice daily with a high-fat meal.
None Documented
None Documented
Approximately 1-2 days in euthyroid patients; shorter in hyperthyroidism, prolonged in hypothyroidism. Clinical context: requires monitoring of thyroid function tests for dose adjustment.
18 hours; prolonged in renal impairment (up to 45 hours in CrCl <30 mL/min)
Primarily renal (approximately 50% as unchanged drug and metabolites); minor biliary/fecal elimination.
Renal: 85% as unchanged drug; Fecal: 10% as metabolites
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone